Oxaliplatin

Correlation of ERCC1 expression in peripheral blood lymphocytes with outcomes of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy

Y. Y. Zhang, Gu, K. S., Wu, H. Y., Yang, F., Bu, L. J., Zhao, C. C., and Zhang, Y. R., Correlation of ERCC1 expression in peripheral blood lymphocytes with outcomes of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy, vol. 14, pp. 15921-15929, 2015.

Excision repair cross-complementing gene-1 (ERCC1) is a key regulatory enzyme whose expression patterns in tumor tissues are associated with survival in gastric cancer. The present study aimed to evaluate the effects of ERCC1 expression in peripheral blood lymphocytes (PBLs) on the outcome of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy. Tumor and PBL samples from 48 patients treated with adjuvant oxaliplatin-based chemotherapy for gastric cancer were analyzed. Immunohistochemistry was used to assess the expression of ERCC1.

Gene and protein expression in the oxaliplatin-resistant HT29/L-OHP human colon cancer cell line

Z. Xiang, Kang, Q. J., and Xiang, X., Gene and protein expression in the oxaliplatin-resistant HT29/L-OHP human colon cancer cell line, vol. 14, pp. 11013-11022, 2015.

Oxaliplatin (L-OHP) is one of the most commonly used anticancer drugs in adjuvant treatment of colon cancer after complete resection of the primary tumor and treatment of metastatic colorectal cancer. Cancer cells eventually become resistant to L-OHP, which diminishes its curative effect. However, the mechanism of action of L-OHP remains unknown. In this study, an L-OHP-resistant human colon cancer cell line, HT29/L-OHP, was established by gradually increasing the dose of L-OHP in culture.

Subscribe to Oxaliplatin